Hamid Emamekhoo, MD
Hematology & Oncology · Madison, WINPI 1053602342
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (46.7%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by Exelixis Inc. at 32.3% of the total. Reporting peaked in 2020 at $5,723 and has fallen 94.1% since, to $336 in 2025.
Across 47 payments — averaging $491.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Exelixis Inc.$7K
- E.r. Squibb & Sons, L.L.C.$5K
- Seagen Inc.$3K
- Johnson & Johnson$2K
- AVEO Pharmaceuticals, Inc.$2K
- Eisai Inc.$2K
- plus $1K from 5 others
Across 84 payments — averaging $30,905 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$1.4M
- Bristol Myers Squibb$435K
- Janssen Research & Development, LLC$210K
- Exelixis Inc.$193K
- E.r. Squibb & Sons, L.L.C.$182K
- Novartis$94K
- plus $108K from 2 others
What the payments were for
- Consulting fees$10,79847%
- Speaking & faculty fees$7,82234%
- Travel & lodging$3,00613%
- Food & beverage$1,4886%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Exelixis Inc. | 14 | $7,477 |
| E.r. Squibb & Sons, L.L.C. | 10 | $4,982 |
| Seagen Inc. | 2 | $3,220 |
| Johnson & Johnson | 3 | $2,401 |
| AVEO Pharmaceuticals, Inc. | 2 | $2,235 |
| Eisai Inc. | 3 | $1,702 |
| AstraZeneca | 2 | $512 |
| Pfizer | 2 | $282 |
| Pharmacyclics LLC, An Abbvie Company | 6 | $150 |
| Cardinal Health 110 LLC | 1 | $100 |
| Sumitomo Pharma America, Inc. | 2 | $54 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$23,114 in reported general payments places this provider in the 85th percentile of 248 hematology & oncology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CabometyxCabozantinib S-Malate | 24 | $595,553 |
| XtandiEnzalutamide | 34 | $459,643 |
| OrgovyxRelugolix | 19 | $47,887 |
| Abiraterone Acetate | 37 | $13,260 |
| Prednisone | 120 | $776 |
| Bicalutamide | 21 | $507 |
| Dexamethasone | 16 | $417 |
| Ondansetron Hcl | 40 | $357 |
| Duloxetine Hcl | 13 | $221 |
| Amlodipine Besylate | 39 | $153 |
| Levothyroxine Sodium | 26 | $125 |
| Lisinopril | 13 | $70 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Exelixis Inc.Cabometyx | $7,477 | $595,55324 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $54 | $47,88719 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 248 hematology & oncology providers in Wisconsin.
Other hematology & oncology in Madison
- Vincent MaMadison$37K
- Priyanka PophaliMadison$32K
- Elisavet PaplomataMadison$21K
- Timothy SchmidtMadison$19K
- Sima Ehsani ChimehMadison$17K
- Kalyan Vara Ganesh NadimintiMadison$17K
- Christos KyriakopoulosMadison$16K
- Matthew BrunnerMadison$15K
- Lyndsey RunaasMadison$12K
- Michael FrontieraMadison$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.